A precision-antidepressant selection platform combining clinical follow-up, ¹H-NMR pharmacometabolomics, pharmacogenomics, machine learning and AI-supported interpretation.
Imperion Biotechnology is contributing to a precision-psychiatry collaboration designed to support more informed antidepressant selection in Major Depressive Disorder.
The programme combines structured clinical characterization, patient follow-up, standardized biospecimen collection, ¹H-NMR pharmacometabolomic analysis, pharmacogenetic and pharmacogenomic validation, and machine-learning-assisted interpretation.
This work reflects a broader shift in psychiatry: moving from trial-and-error treatment selection toward biologically informed decision systems.